Semaglutide: The Truth Behind Wegovy, Alzheimer’s, and What No Influencer Will Tell You

If you’ve been keeping an eye on health trends or have simply walked past a pharmacy in recent months, you’ve surely heard about semaglutide. It’s that complicated name everyone associates with the famous weight-loss pen, but trust me, the story goes far beyond mirror selfies or the miracle prescriptions we see on social media. As someone who’s covered the pharmaceutical industry for years, I’m going to tell you what’s really happening, especially after data leaked from international conferences that took the conversation in an unexpected direction.

The boom of the famous "pen" and what lies beneath

The arrival of medications like Wegovy and Ozempic revolutionised how we view the treatment of diabetes and obesity. In cities like Dublin or Cork, it’s not unusual to hear someone asking for Wegovy 0.25mg, that specific presentation that comes in a box with a pre-filled injection system containing 1.5mL of solution for subcutaneous use plus 4 Novofine Plus needles. It’s the starter dose, the one many seek out to begin treatment. But here’s the first hard truth: this is not a toy. When I see semaglutide being sold as a magic solution to drop five kilos in a month without breaking a sweat, it makes my blood boil. Because it’s a potent drug, and like any potent drug, it comes with rules.

The news no one saw coming: Is the hope for an Alzheimer’s treatment gone?

A few months ago, the scientific community was buzzing with excitement. There was a genuine hope that semaglutide wouldn’t just help with weight or glucose, but could act as a shield against Alzheimer’s. Studies suggested a neuroprotective effect, a potential to slow cognitive decline. It felt like finding an added bonus in something already working. However, as is often the case, reality has just given us a harsh wake-up call.

Just a few weeks ago, during the conclusion of the long-awaited Phase III clinical trials, the verdict was clear: semaglutide did not succeed in slowing the progression of mild Alzheimer’s. It was a tough read going through the internal report, because I know many families here, caring for loved ones with this disease, had pinned their hopes on it. The data, which we in the industry handle carefully, showed that while the drug works wonders on metabolism, when it comes to memory loss and cognitive function, there was simply no significant difference between those taking the drug and those on a placebo. It’s a dead stop for one of the most exciting hypotheses put forward in recent years.

What you should know if you’re already using semaglutide

That it doesn’t work for Alzheimer’s doesn’t take away from its effectiveness for what it’s approved for. But here’s where I want to be straight with you, because in my experience, people tend to skip steps. If you’re considering using Wegovy 0.25mg or any presentation, keep this in mind:

• It’s not for everyone: The initial 0.25mg dose is designed to let your body adjust. Skipping the dose or starting with a higher one could land you straight in hospital with pancreatitis.
• The injection system isn’t optional: That "pre-filled injection system with 1.5mL subcutaneous solution" isn’t just for show. How you administer it and the Novofine Plus needles are designed to minimise pain and ensure the dose is accurate.
• It’s a treatment, not a one-month fad: Semaglutide works while you’re using it. I’ve seen cases of people using it for an event and then stopping, only to gain back even more weight. This is a long-term commitment, if your doctor determines it’s right for you.

The Irish factor and the grey market

Here in Ireland, we have a particular relationship with medication. There’s a tendency towards self-prescribing and the notion of getting "just a little bit" of something. With semaglutide, it’s been chaotic. I’ve seen sellers being shared on WhatsApp groups offering "generic Wegovy" or the "diabetic version" as if they were sweets. I’m telling you this with the confidence of someone who has seen both sides of the coin: don’t take the risk. The Novofine Plus needles that come in the official box aren’t a luxury; they’re part of a safety protocol. Buying this on the unofficial market is playing Russian roulette with your health.

The failure of the studies to halt Alzheimer’s isn’t bad news in itself; it’s an invitation to keep our feet on the ground. Science progresses, sometimes with setbacks, but it keeps moving forward. Semaglutide is an incredibly useful tool for those who genuinely need it under medical supervision. For everyone else, the lesson is clear: don’t look for shortcuts, especially when it comes to your brain and your overall well-being. If your doctor prescribed it, trust the process, respect the dosage, and that subcutaneous injection system. If you only want it for the trend, maybe it’s time to sit and think about whether it’s worth playing with fire.